Ali Salanti
CEO, Professor Var2 Pharmaceuticals
Seminars
Tuesday 9th March 2027
From Immuno-PET to Phase 1: Translating VARTUMAB Oncofetal Chondroitin Sulfate Targeting into an ADC Therapy
1:45 pm
- Demonstrating effective tumour knockdown through targeting oncofetal chondroitin sulfate across cancer cells, circulating tumour cells, and tumour stromal cells
- Achieving clinical validation of tumour targeting by immuno-PET in 16 cancer patients
- Spotlighting GLP toxicology and Phase 1 clinical trial design
